Free Breast Cancer CE/CME

23rd Annual School of Breast Oncology® Curriculum

Joyce O’Shaughnessy, MD

School of Breast Oncology® (SOBO) Slide & Lecture Library

Joyce O’Shaughnessy, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

BURST CME™ Activity 3: Exploring Combination Strategies in HR+/HER2– MBC: Where Do Oral SERDs Fit In?

Erica L. Mayer, MD, MPH; Jason Aboudi Mouabbi, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Project ECHO®: From Evidence to Action: Integrating New ADC Approaches to Optimize Treatment Sequencing in mTNBC

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Y…

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Seth A. Wander, MD, PhD; Reshma L. Mahtani, DO; Shanu Modi, MD; Joyce O’Sha…

Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

Joyce O’Shaughnessy, MD; Sarat Chandarlapaty, MD, PhD; Mitchell Elliott, MD…

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 2)

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 1)

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

Introducing Novel Treatment Paradigms for Metastatic TNBC

Aditya Bardia, MD, MPH, FASCO; Alexis LeVee, MD

Key Considerations for Health Equity and Patient-Centered Care in TNBC

Aditya Bardia, MD, MPH, FASCO; Kathryn E. Post, PhD, ANP-BC

Current Approaches and Future Directions for Early-Stage TNBC

Nour Abuhadra, MD; Antonio Giordano, MD, PhD

From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

Satellite Symposia at the Annual Radiation Oncology Meeting

September 27-28, 2026

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Webinar Series

Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD

BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base

Adam Brufsky, MD, PhD; Manali Bhave, MD

BURST CME™ Activity 1: Foundations of Endocrine Resistance and Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Adam Brufsky, MD, PhD; Manali Bhave, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisbe…

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Ja…

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us

Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD…

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

February 6, 2027

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Taran…

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, …

Rhode Island Oncology Society

2 Sessions are Available!

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry She…

OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; Seth A. Wander, MD, P…

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, …

Medical Crossfire®: Translating Risk into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Ann H. Partridge, MD, MPH; William J. Gradishar, MD, FASCO, FACP; Saranya C…

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, M…

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, …

Show Me the Data™: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; Irene Kang, MD

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; …

Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; Priyanka Sharma, MD, FASCO

Medical Crossfire®: Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, …

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, P…

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD